New drug combo for advanced bile duct and gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two new drugs, AK130 and AK112, for people with advanced bile duct or gallbladder cancer that has stopped responding to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bile duct or gallbladder cancer that got worse after one prior treatment.
- You are able to get out of bed and care for yourself (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan and has not been treated with radiation.
- Your major organs (like liver, kidneys, bone marrow) are working well enough.
- You have not had another cancer in the last 3 years (except certain early or skin cancers).
- You do not have cancer that has spread to the brain or fluid buildup in your chest or belly that needs draining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combo—disitamab vedotin, lenvatinib, and an immunotherapy—for people with advanced bile duct cancer that has HER2 protein. It aims to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy (GemOX) and lenvatinib can shrink tumors enough so that bile duct or gallbladder cancers that could not be removed initially become eligible for surgery. It is an option for people with advanced but not yet spread cancer who have not received prior treatment.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two investigational drugs, AK130 and AK112, for people with advanced pancreatic cancer. It may be an option if you have had 1 or 2 prior treatments and are still relatively healthy.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.